BMP‑2 and miR‑29c in osteosarcoma tissues on proliferation and invasion of osteosarcoma cells

Chen,Xueqing; Zhang,Yingjian

doi:10.3892/ol.2019.10229

BMP‑2 and miR‑29c in osteosarcoma tissues on proliferation and invasion of osteosarcoma cells

Authors:
- Xueqing Chen
- Yingjian Zhang
View Affiliations

Affiliations: Department of Orthopedics, Tianjin Baodi Hospital, Tianjin 301800, P.R. China
Published online on: April 8, 2019 https://doi.org/10.3892/ol.2019.10229
Pages: 5389-5394

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of bone morphogenetic protein (BMP)‑2 and microRNA (miR)‑29c in osteosarcoma tissues and effects on proliferation and invasion of osteosarcoma cells were investigated. A retrospective analysis of 75 patients with osteosarcoma who underwent surgery in Tianjin Baodi Hospital from May 2013 to June 2017 was conducted. A total of 75 osteosarcoma tissues and 51 normal paraneoplastic tissues were collected. RT‑PCR was used to compare the expression difference of BMP‑2 and miR‑29c. miR‑29c mimics (experimental group A) and BMP‑2 siRNA plasmid (experimental group B) were transfected into human osteosarcoma cells MG‑63, respectively. The transfected cells were divided into miRNA negative control (miR‑NC) group (cells transfected with miR‑negative control), siRNA negative control group (cells transfected with non‑silent siRNA) and blank group (cells without any transfection). MTT assay was used to detect cell proliferation in each group at different time periods. Transwell insert was used to detect invasion of cells in vitro. The relative expression of BMP‑2 in osteosarcoma tissue was significantly higher than that in paraneoplastic tissue (P<0.05). Τhe relative expression of miR‑29c in osteosarcoma tissue was significantly lower than that in paraneoplastic tissue (P<0.05). The cell survival rates in experimental groups A and B were significantly lower than those in the blank, miR‑NC negative control and siRNA negative control groups on day 5 (P<0.05). The number of cell transmembranes in experimental groups A and B was significantly lower than those in the blank, miR‑NC negative control and siRNA negative control groups (P<0.05). BMP‑2 is over‑expressed in osteosarcoma tissues, and miR‑29c is under‑expressed in osteosarcoma tissues. Interfering with the expression of BMP‑2 and overexpression of miR‑29c can inhibit the proliferation and invasion of osteosarcoma cells, indicating that BMP‑2 and miR‑29c may be involved in the regulation of proliferation and metastasis of osteosarcoma cells and could be used as new molecular target markers for the diagnosis and treatment of osteosarcoma.

View Figures

View References

1	Anderson ME: Update on survival in osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
2	Fagioli F, Biasin E, Mereuta OM, Muraro M, Luksch R, Ferrari S, Aglietta M and Madon E: Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transplant. 41 (Suppl 2):S131–S134. 2008. View Article : Google Scholar : PubMed/NCBI
3	Lin BC, Huang D, Yu CQ, Mou Y, Liu YH, Zhang DW and Shi FJ: MicroRNA-184 modulates doxorubicin resistance in osteosarcoma cells by targeting BCL2L1. Med Sci Monit. 22:1761–1765. 2016. View Article : Google Scholar : PubMed/NCBI
4	Bacci G, Balladelli A, Palmerini E, Alberghini M, Pollastri P, Galletti S, Mercuri M and Picci P: Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience. J Pediatr Hematol Oncol. 30:908–912. 2008. View Article : Google Scholar : PubMed/NCBI
5	Li W, Xie P and Ruan WH: Overexpression of lncRNA UCA1 promotes osteosarcoma progression and correlates with poor prognosis. J Bone Oncol. 5:80–85. 2016. View Article : Google Scholar : PubMed/NCBI
6	Bacci G, Ruggieri P, Bertoni F, Ferrari S, Longhi A, Biagini R, Zavatta M, Versari M and Forni C: Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience. Oncol Rep. 7:1129–1133. 2000.PubMed/NCBI
7	Chen G, Fang T, Huang Z, Qi Y, Du S, Di T, Lei Z, Zhang X and Yan W: MicroRNA-133a inhibits osteosarcoma cells proliferation and invasion via targeting IGF-1R. Cell Physiol Biochem. 38:598–608. 2016. View Article : Google Scholar : PubMed/NCBI
8	Liu P, Man Y, Wang Y and Bao Y: Mechanism of BMP9 promotes growth of osteosarcoma mediated by the Notch signaling pathway. Oncol Lett. 11:1367–1370. 2016. View Article : Google Scholar : PubMed/NCBI
9	Chang L, Shrestha S, LaChaud G, Scott MA and James AW: Review of microRNA in osteosarcoma and chondrosarcoma. Med Oncol. 32:6132015. View Article : Google Scholar : PubMed/NCBI
10	Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et al: miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
11	Jiang J, Yu C, Chen M, Zhang H, Tian S and Sun C: Reduction of miR-29c enhances pancreatic cancer cell migration and stem cell-like phenotype. Oncotarget. 6:2767–2778. 2015.PubMed/NCBI
12	Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, Liu X, Zhang Y and Le H: Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One. 9:e877802014. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Velletri T, Xie N, Wang Y, Huang Y, Yang Q, Chen X, Chen Q, Shou P, Gan Y, Cao G, et al: P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development. Cell Death Dis. 7:e20152016. View Article : Google Scholar : PubMed/NCBI
15	Ruan WD, Wang P, Feng S, Xue Y and Zhang B: MicroRNA-497 inhibits cell proliferation, migration, and invasion by targeting AMOT in human osteosarcoma cells. OncoTargets Ther. 9:303–313. 2016. View Article : Google Scholar
16	Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou OA, Largaespada D, et al: A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma. Cancer Discov. 5:920–931. 2015. View Article : Google Scholar : PubMed/NCBI
17	Yi C, Li X, Xu W and Chen A: Relationship between the expression of MTA-1 gene and the metastasis and invasion in human osteosarcoma. J Huazhong Univ Sci Technolog Med Sci. 25:445–447. 2005. View Article : Google Scholar : PubMed/NCBI
18	Wang L, Park P, Zhang H, La Marca F, Claeson A, Valdivia J and Lin CY: BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. Cancer Biol Ther. 11:457–463. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hong Q, Fang J, Pang Y and Zheng J: Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. Med Oncol. 31:372014. View Article : Google Scholar : PubMed/NCBI
20	Yu L, van der Valk M, Cao J, Han CY, Juan T, Bass MB, Deshpande C, Damore MA, Stanton R and Babij P: Sclerostin expression is induced by BMPs in human Saos-2 osteosarcoma cells but not via direct effects on the sclerostin gene promoter or ECR5 element. Bone. 49:1131–1140. 2011. View Article : Google Scholar : PubMed/NCBI
21	Gobbi G, Sangiorgi L, Lenzi L, Casadei R, Canaider S, Strippoli P, Lucarelli E, Ghedini I, Donati D, Fabbri N, et al: Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol. 20:143–147. 2002.PubMed/NCBI
22	Huo L, Liu K, Pei J, Yang Y, Ye Y, Liu Y, Sun J, Han H, Xu W and Gao Y: Fluoride promotes viability and differentiation of osteoblast-like Saos-2 cells via BMP/Smads signaling pathway. Biol Trace Elem Res. 155:142–149. 2013. View Article : Google Scholar : PubMed/NCBI
23	Liu N, Tang LL, Sun Y, Cui RX, Wang HY, Huang BJ, He QM, Jiang W and Ma J: MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett. 329:181–188. 2013. View Article : Google Scholar : PubMed/NCBI
24	Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D and Lagneaux L: microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 113:5237–5245. 2009. View Article : Google Scholar : PubMed/NCBI
25	Lawrie CH, Ballabio E, Dyar OJ, Jones M, Ventura R, Chi J, Tramonti D, Gooding S, Boultwood J, Wainscoat JS, et al: MicroRNA expression in chronic lymphocytic leukaemia. Br J Haematol. 147:398–402. 2009. View Article : Google Scholar : PubMed/NCBI
26	Gao S, Cheng C, Chen H, Li M, Liu K and Wang G: IGF1 3′UTR functions as a ceRNA in promoting angiogenesis by sponging miR-29 family in osteosarcoma. J Mol Histol. 47:135–143. 2016. View Article : Google Scholar : PubMed/NCBI
27	Guo W, Gorlick R, Ladanyi M, Meyers PA, Huvos AG, Bertino JR and Healey JH: Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop Relat Res. 365:175–183. 1999. View Article : Google Scholar
28	Di Fiore R, Drago-Ferrante R, Pentimalli F, Di Marzo D, Forte IM, D'Anneo A, Carlisi D, De Blasio A, Giuliano M, Tesoriere G, et al: MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells. Int J Oncol. 45:2013–2023. 2014. View Article : Google Scholar : PubMed/NCBI
29	Chen G, Zhou T, Li Y, Yu Z and Sun L: p53 target miR-29c-3p suppresses colon cancer cell invasion and migration through inhibition of PHLDB2. Biochem Biophys Res Commun. 487:90–95. 2017. View Article : Google Scholar : PubMed/NCBI